INTERLACE
A phase III multicentre trial of weekly induction chemotherapy followed by standard chemoradiation versus standard chemoradiation alone in patients with locally advanced cervical cancer.
NCRI
STATEC
A randomised trial of non-Selective versus selective adjuvant Therapy in high risk Apparent sTage 1 Endometrial Cancer
Trial Number
NCT02566811 (ClinicalTrials.gov Identifier)Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number
ICON7
A randomised, two arm, multi-centre Gynaecologic Cancer InterGroup phase III trial of adding bevacizumab to standard chemotherapy (carboplatin and paclitaxel) in first line treatment of patients with epithelial ovarian cancer.
Trial Number
NCT00483782 (ClinicalTrials.gov Identifier)Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number
ICON6
A randomised trial of concurrent cediranib [AZD2171] (with platinum-based chemotherapy) and maintenance cediranib in women with platinum-sensitive relapsed ovarian cancer.
Trial Number
NCT00532194 (ClinicalTrials.gov Identifier)Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number
mEOC
A GCIG Intergroup multicentre trial of open label carboplatin and paclitaxel +/- bevacizumab compared with oxaliplatin and capecitabine +/- bevacizumab as first line chemotherapy in patients with mucinous Epithelial Ovarian Cancer.
Trial Number
ISRCTN83438782 (ISRCTN Registry)Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number
ICON9
An international phase III randomised study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy
Trial Number
NCT03278717 (ClinicalTrials.gov Identifier)Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number
ICON8/ICON8B
An international phase III randomised trial of dose-fractionated chemotherapy compared to standard three-weekly chemotherapy, following immediate primary surgery or as part of delayed primary surgery, for women with newly diagnosed epithelial ovarian, fallopian tube or primary peritoneal cancer
Trial Number
NCT01654146 (ClinicalTrials.gov Identifier)Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number
CHORUS
A Randomized Feasibility Trial to Determine the Impact of Timing of Surgery and Chemotherapy in Newly Diagnosed Patients with Advanced Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma